Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology
-
By
-
June 23, 2026
-
4 min
By
June 23, 2026
by
June 23, 2026
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.
June 26, 2026
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
July 1, 2026
Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.
June 25, 2026